TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

NCT01052883 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
DRUG: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
DRUG: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
DRUG: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab

Sponsor

Tibotec Pharmaceuticals, Ireland